Literature DB >> 17581719

2-[Fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography versus whole-body diffusion-weighted MRI for detection of malignant lesions: initial experience.

Tsuyoshi Komori1, Isamu Narabayashi, Kaname Matsumura, Mitsuru Matsuki, Hiroyuki Akagi, Yasuharu Ogura, Fumitoshi Aga, Itaru Adachi.   

Abstract

OBJECTIVES: The new magnetic resonance whole body diffusion-weighted imaging with background body signal suppression (DWIBS) uses short tau inversion recovery-echo planar imaging sequence under normal respiration. DWIBS is different from 2-[fluorine-18]-fluoro-2-deoxy-D: -glucose positron emission tomography ((18)F-FDG PET) imaging in technology, but their images are similar. We compared the two modalities regarding the detection and characterization of malignant tumors.
METHODS: DWIBS and (18)F-FDG PET/computed tomography (CT) were performed on 16 cancer patients on the same day. The diagnoses were the following: lung cancer (n = 12), colon cancer (n = 2), breast cancer (n = 1), and pulmonary metastasis (n = 1). A total of 27 malignant tumors (15 lung cancer, 5 pulmonary metastases of parathyroid cancer, 3 pulmonary metastases of lung cancer, 3 colon cancer, 1 breast cancer) and seven reference organs around malignant lesions (two liver regions, four normal lymph nodes, one muscle region) were evaluated visually and quantitatively using the apparent diffusion coefficient (ADC) (x10(-3) mm(2)/s) and standardized uptake value (SUV).
RESULTS: Twenty-five (92.6%) of the 27 malignant lesions were detected visually with DWIBS imaging in contrast to 22 malignant tumors (81.5%) with (18)F-FDG PET/CT imaging. The quantitative evaluation showed that there was a significant difference between the mean SUVs of the reference organs (n = 7, 1.48 +/- 0.62) and the malignant (n = 22, 5.36 +/- 2.80) lesions (P < 0.01). However, there was no significant difference between the mean ADCs of the reference organs (n = 7, 1.54 +/- 0.24) and the malignant (n = 25, 1.18 +/- 0.70) lesions.
CONCLUSIONS: DWIBS can be used for the detection of malignant tumors or benign tumors; however, it may be difficult to differentiate between benign and malignant lesions by ADC.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17581719     DOI: 10.1007/s12149-007-0010-6

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  35 in total

1.  Whole-body diffusion-weighted magnetic resonance imaging with apparent diffusion coefficient mapping for staging patients with diffuse large B-cell lymphoma.

Authors:  Chieh Lin; Alain Luciani; Emmanuel Itti; Taoufik El-Gnaoui; Alexandre Vignaud; Pauline Beaussart; Shih-jui Lin; Karim Belhadj; Pierre Brugières; Eva Evangelista; Corinne Haioun; Michel Meignan; Alain Rahmouni
Journal:  Eur Radiol       Date:  2010-03-23       Impact factor: 5.315

2.  A case of adult onset Still's disease showing marked accumulation in the liver and spleen, on positron emission tomography-CT images.

Authors:  Masanori Funauchi; Shinya Ikoma; Kazuya Kishimoto; Hideki Shimazu; Yuji Nozaki; Masafumi Sugiyama; Koji Kinoshita
Journal:  Rheumatol Int       Date:  2008-04-29       Impact factor: 2.631

3.  Comparing diffusion-weighted imaging and positron emission tomography for pulmonary nodules measuring from 1 to 3 cm in size.

Authors:  Hiroaki Nomori; Yue Cong; Hiroshi Sugimura; Yoshiaki Kato
Journal:  Surg Today       Date:  2015-02-13       Impact factor: 2.549

4.  Diffusion-weighted MR imaging in gynecologic cancers.

Authors:  Shigenobu Motoshima; Hiroyuki Irie; Takahiko Nakazono; Toshiharu Kamura; Sho Kudo
Journal:  J Gynecol Oncol       Date:  2011-12-05       Impact factor: 4.401

5.  Improved short tau inversion recovery (iSTIR) for increased tumor conspicuity in the abdomen.

Authors:  Ananth J Madhuranthakam; Karen S Lee; Aya Yassin; Jean H Brittain; Ivan Pedrosa; Neil M Rofsky; David C Alsop
Journal:  MAGMA       Date:  2013-09-20       Impact factor: 2.310

6.  Diffusion-weighted imaging with background body signal suppression (DWIBS) distinguishes benign lesions from malignant pulmonary solitary lesions.

Authors:  Chunli Zhao; Dong Deng; Wei Ye; Liling Long; Yumin Lu; Youyong Wei
Journal:  Am J Transl Res       Date:  2021-01-15       Impact factor: 4.060

7.  Whole-body MR-DWIBS vs. [18F]-FDG-PET/CT in the study of malignant tumors: a retrospective study.

Authors:  D Cafagna; G Rubini; F Iuele; N Maggialetti; A Notaristefano; D Pinto; A Niccoli-Asabella; G Palmiotti; M Lasciarrea; A Maggialetti
Journal:  Radiol Med       Date:  2011-07-09       Impact factor: 3.469

8.  Comparison of diffusion-weighted whole body MRI and skeletal scintigraphy for the detection of bone metastases in patients with prostate or breast carcinoma.

Authors:  Andreas Gutzeit; Aleksis Doert; Johannes M Froehlich; Boris P Eckhardt; Andreas Meili; Patrick Scherr; Daniel T Schmid; Nicole Graf; Constantin A von Weymarn; Edwin M M Willemse; Christoph A Binkert
Journal:  Skeletal Radiol       Date:  2010-04       Impact factor: 2.199

Review 9.  Whole-body diffusion-weighted and proton imaging: a review of this emerging technology for monitoring metastatic cancer.

Authors:  Michael A Jacobs; Li Pan; Katarzyna J Macura
Journal:  Semin Roentgenol       Date:  2009-04       Impact factor: 0.800

Review 10.  Diffusion-weighted whole-body imaging with background body signal suppression (DWIBS): features and potential applications in oncology.

Authors:  Thomas C Kwee; Taro Takahara; Reiji Ochiai; Rutger A J Nievelstein; Peter R Luijten
Journal:  Eur Radiol       Date:  2008-04-30       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.